Eli Lilly (LLY)

Andel launches a PBM-free employer platform offering Eli Lilly and Company's (NYSE: LLY) Zepbound KwikPen at lower cash prices. CEO Jay Bregman tells Benzinga how the model works and why PBMs can't copy it.

Viking says it needs only about 5%-10% market share to succeed in the obesity market, despite competition from Eli Lilly and Novo Nordisk.

Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.

On a day marked by deepening global uncertainty and a sharp spike in energy costs, the healthcare sector emerged as the primary beneficiary of a massive "risk-off" migration by institutional investors. As of the market close on March 10, 2026, the Healthcare Select Sector SPDR Fund (NYSEARCA:XLV) gained 1%

Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.

The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry darlings. As of March 10, 2026, the industry is processing a tale of two trajectories: Vertex Pharmaceuticals (NASDAQ: VRTX) has cemented

The long-held dominance of Novo Nordisk (NYSE: NVO) in the global obesity market has been dealt a staggering blow following the release of the "worst-case scenario" results from the REDEFINE 4 Phase 3 trial. For years, the Danish pharmaceutical giant was the undisputed leader of the GLP-1 revolution, but the

As per the CEO, the company will have four late-stage trials by the end of 2026.

These companies' shares have fallen too far, offering investors an attractive opportunity.

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering "hangover" period in 2023 and 2024, the pharmaceutical giant is currently in the middle of a high-stakes transformation. The company is attempting to [...]

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a decade. Driven by a historic flood of "dry powder" and a rapidly stabilizing macroeconomic environment,

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most critical juncture in its nine-year history. Once viewed as a disruptive "millennial-focused" telehealth startup specializing in hair loss and sexual health, the company [...]

In a matter of months, last year's winners have shifted to losers, creating compelling buying opportunities for long-term investors.

Eli Lilly may be the GLP-1 leader, but its valuation is stretched.

This Dividend King is out of favor, and this medical device peer has just introduced an exciting new product.

These companies have a lot more to offer than their prospects in the weight loss market.

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Things can't get that much worse for the drugmaker.

Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.